Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I^TM), ranging from target validation and antibody discovery through preclinical research, announced a collaboration with Kodiak Sciences Inc. (Nasdaq: KOD). This partnership aims to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona's proprietary Harbour Mice^® fully human antibody platform.

The Harbour Mice^® platform generates fully human monoclonal antibodies in both the two heavy and two light chains (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. The HCAb Harbour Mice^® platform, in particular, is transforming antibody development by producing unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. Under the agreement, Kodiak Sciences gains the right to use both the H2L2 and HCAb Harbour Mice^® platforms in multiple programs for therapeutic antibody discovery and development.

"We are pleased to collaborate with Kodiak Sciences to advance novel antibody therapies for ophthalmic diseases," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. "This agreement further validates our proprietary Harbour Mice^® technology platform. With Nona's industry-leading technology and expertise, we look forward to supporting Kodiak Sciences in accelerating their next-generation therapeutic antibody development and bringing more innovative therapies to patients." 

"Retinal diseases involve a complex etiology, so advancing more effective therapies will require targeting multiple pathways at once," said Victor Perlroth, M.D., Chairman and CEO of Kodiak Sciences Inc. "We are thrilled to announce our partnership with Nona Biosciences, leveraging their advanced Harbour Mice^® platforms and robust expertise in antibody discovery. This collaboration will accelerate our mission to create next generation biotherapeutics, combining our strengths to bring innovative treatments to patients in need."